By Bharath Rajeswaran and Vivek Kumar M (Reuters) -Indian stock benchmarks fell on Friday, logging their fifth straight ...

With US markets touching all-time highs, foreign markets being relatively cheaper, and global investors being over-indexed to ...

The 2025 edition of the Blue-Chip Ratio was released this week, providing an annual snapshot at the teams that have been ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Once a prized recruit, Evans was placed on the Jets' reserve/retired list Monday with just 10 career games played ...

On July 24, Emily Roland, Manulife John Hancock Investments co-chief investment strategist, appeared on CNBC’s ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Here's a closer look at five potential breakout candidates among former Midwest four- and five-stars in the Big Ten.

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Blue chip stocks, also known as large cap stocks (because the companies have a high market capitalization of $1 billion or more), tend to rise and fall in conjunction with the stock market in general.

Blue chips are favored by investors who want to balance low-risk investing with long-term growth potential and income. Generally, blue-chip stocks have a long-established history of profitability ...